Using a small pilot proteomic dataset of 38 patients, we focus on two drugs that target the FLT3 and Ras/MEK pathways in AML (quizartinib and trametinib respectively) and evaluate how the genes, transcripts and proteins measured in each patient sample correlate with drug sensitivity. Here, FLT3 is linked to acute myeloid leukemia.